| Companies sponsors |
Menarini Stemline (elacestrant) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Breast Cancer Now |
| |
Make 2nds Count |
| |
MET UP UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
UK Breast Cancer Group |
| Associated public health groups |
None |
| Comparator companies |
Amarox (anastrozole, capecitabine, letrozole) (confidentiality agreement not signed, not participating) |
| |
AstraZeneca (anastrozole, fulvestrant) (confidentiality agreement signed, participating) |
| |
Aurobindo Pharma – Milpharm (tamoxifen) (confidentiality agreement not signed, not participating) |
| |
Bristol Myers Squibb Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Cipla EU (fulvestrant, letrozole) (confidentiality agreement not signed, not participating) |
| |
Dr. Reddy’s Laboratories (capecitabine, everolimus, fulvestrant) (confidentiality agreement not signed, not participating) |
| |
Eisai (eribulin) (confidentiality agreement signed, participating) |
| |
Ethypharm (everolimus) (confidentiality agreement not signed, not participating) |
| |
Genus Pharmaceuticals (fulvestrant) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals (capecitabine, exemestane, fulvestrant, letrozole) (confidentiality agreement not signed, not participating) |
| |
Hospira UK (docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating) |
| |
Medical Valley (fulvestrant) (confidentiality agreement not signed, not participating) |
| |
Mylan (anastrozole, exemestane, tamoxifen) (confidentiality agreement not signed, not participating) |
| |
Novartis (alpelisib, everolimus, letrozole) (confidentiality agreement signed, participating) |
| |
Pfizer (exemestane) (confidentiality agreement signed, participating) |
| |
Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating) |
| |
Ranbaxy, a Sun Pharmaceuticals company (anastrozole, fulvestrant, gemcitabine, letrozole) (confidentiality agreement not signed, not participating) |
| |
Rivopharm (exemestane) (confidentiality agreement not signed, not participating) |
| |
Rosemont Pharmaceuticals (tamoxifen) (confidentiality agreement not signed, not participating) |
| |
Sandoz (anastrozole, everolimus, fulvestrant) (confidentiality agreement not signed, not participating) |
| |
Seacross Pharmaceuticals (docetaxel, paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating) |
| |
Teva UK (fulvestrant, paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Tillomed Laboratories (tamoxifen) (confidentiality agreement not signed, not participating) |
| |
Wockhardt UK (tamoxifen) (confidentiality agreement not signed, not participating) |
| |
Zentiva (exemestane, fulvestrant) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |